Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Genzyme begins phase II cardio trial
Genzyme’s experimental therapy, using Ad2/HIF-1 alpha, an engineered form of the HIF-1 alpha gene, is designed to promote the growth of new blood vessels and improve circulation in
Genzyme’s experimental therapy, using Ad2/HIF-1 alpha, an engineered form of the HIF-1 alpha gene, is designed to promote the growth of new blood vessels and improve circulation in
Data from the pilot study, which evaluated the safety and efficacy of Hyalgan (sodium hyaluronate) versus saline in the treatment of osteoarthritis (OA) of the ankle, suggested that
DOV 102,677 is believed to be a potent inhibitor of serotonin, norepinephrine and dopamine reuptake, with preferential action on the dopamine transporter protein. This clinical trial is a
The phase II clinical trial is an open-label study to evaluate the efficacy, safety and tolerability of HGS-ETR1 (mapatumumab) in patients with relapsed or refractory colorectal cancer. The
The phase I study included patients with progressive prostate disease after primary surgery or radiotherapy. The dose-escalation study sought to determine the optimal and safe dose range of
The agreement provides Prolexys with exclusive, worldwide rights to a patent estate covering selective anti-tumor compounds discovered by Dr Brent Stockwell, a former Whitehead fellow and now an
Truvada, which combines the company’s anti-HIV medications Emtriva (emtricitabine) and Viread (tenofovir disoproxil fumarate) in one tablet, has now been granted marketing approval in all 25 member states
The plans have resulted from a strategic program review by the company’s management and board of directors and are part of a move to adopt a more focused
Atacand (candesartan cilexetil) is an angiotensin receptor blocker (ARB), manufactured under license from Takeda, that is already on the market for the treatment of high blood pressure. The
Data from a phase II clinical trial of ZAG-1701, EquiTech’s novel reformulated ibuprofen caplet, showed that ZAG-1701 is absorbed significantly faster and demonstrated a trend toward faster onset